Chris Kresser: Good question. We have been using it regularly. It’s probably done clinic-wide, 25 or 30 panels now, between the different practitioners, at least, maybe more. I’m really liking the test a lot. They’re continuously improving it. They just added Akkermansia on the beneficial bacteria section, which is really important, and then they also now are testing for Archaea. This can be another way of potentially looking at whether someone is likely to have methane-predominant SIBO because if we’re measuring Archaea in the stool, then that’s going to be suggestive of methane production.
We are working on an update right now to update the stool testing section of the course. I’m not sure if we’ll finish it before you folks graduate, but even if that’s not the case, you’ll still have access to the course after you finish so you’ll have access to the updates.